2007'08.26.Sun
ふとん専門店が開店いたしました。
| 2007年08月25日 ふとん専門店 厳選した上質な布団を取り揃えたインターネット通販のお店です。布団セットや、暑い夜を快適に過ごすのに最適な低反発冷却ジェルパッドなども取り揃えております。 |
PR
2007'08.26.Sun
９月３０日（日）★ＮＰＯ兵庫県健康管理士会 ★〔第3回 健康セミナー＆健康管理士 資格取得説明会〕開催
| 2007年08月26日 ★ＮＰＯ兵庫県健康管理士会 ★ ■「メタボ予防は自己管理から」 〔会場アクセス〕 主 催 特定非営利活動法人 兵庫県健康管理士会
病気が多様化し医療費が上昇し続ける現代社会では、予防医学・健康管理が重要です。「健康管理士一般指導員」は、病気だけでなくストレス・栄養・運動・環境等の知識を学び、予防医学の啓発活動や健康カウンセリングを行うことができる資格です。当日は健康管理士の現状や地域・企業での活動報告、また資格取得後の可能性について詳しくご説明します。 ＜＜お申し込み方法＞＞ |
2007'08.26.Sun
洗車の新常識！「出張おまかせ洗車デリデリ☆ウォッシュ」9月1日よりサービス開始！
| 2007年08月26日 中小企業向け顧客システム開発業務と事務効率化及び集客コンサルティング業務を行う（エ－ルアクティブ インコーポレーテッド（福岡県福岡市・代表取締役 有馬 義之介）は9月1日から出張洗車代行サービス「出張おまかせ洗車デリデリ☆ウォッシュ」のサービスを開始する。 《出張専門の洗車代行サービス》 《節水洗車法開発の経緯》 ☆お問い合わせ☆------------------------------------------------- |
2007'08.24.Fri
WuXi PharmaTech CEO Appointed to CrossFire Beilstein Database Advisory Board
August 24, 2007
SHANGHAI, China, Aug. 24 /Xinhua-PRNewswire/ -- WuXi
PharmaTech (NYSE: WX), China's premier provider of
pharmaceutical R&D outsourcing services announced today
Dr. Ge Li, the Company's Chairman and Chief Executive
Officer, is appointed to a newly established advisory board
of Elsevier Information Systems GmbH.
(Logo: http://www.xprn.com/xprn/sa/200611271812-min.jpg
)
Elsevier Information Systems GmbH, a subsidiary of
Elsevier, the leading global publisher of scientific,
technical and medical information, recently established an
Advisory Board in order to further improve the CrossFire
Beilstein Database, the world's largest organic chemistry
and chemical facts database. The Advisory Board consists
of eleven industry experts including two Nobel
laureates¡ªProf. Robert H. Grubbs from California Institute
of Technology and Dr. K. Barry Sharpless from Scripps
Research Institute.
In early 2006 WuXi PharmaTech became the largest
CrossFire Beilstein user in China by number of user seats.
Now the Company is the largest user of the database in the
world by search volume.
"It is a great honor to be a member of such a
notable selection of industry leaders. I am very pleased
to serve in an advisory role for such a high quality drug
discovery and research tool," commented Dr. Ge Li,
Chairman and Chief Executive Officer of WuXi PharmaTech.
"The database is such an indispensable resource that
our scientists rely on it to support the drug discovery
efforts of our global pharmaceutical and biotechnology
clients."
About WuXi PharmaTech Co., Ltd.
Founded in 2000, Shanghai-based WuXi PharmaTech is the
leading China-based pharmaceutical and biotechnology
R&D outsourcing company. As a research- driven and
customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and
integrated portfolio of laboratory and research
manufacturing services throughout the drug discovery and
development process. WuXi PharmaTech's services are
designed to assist its global partners in shortening the
cycle and lowering the cost of drug discovery and
development by providing cost-effective and efficient
outsourcing solutions that save its customers both time and
money. Its operations are grouped into two segments:
laboratory services, consisting of discovery chemistry,
service biology, analytical, pharmaceutical development and
process development services, and manufacturing, focusing on
manufacturing of advanced intermediates and active
pharmaceutical ingredients for R&D use. In 2006, WuXi
PharmaTech provided services to 70 pharmaceutical and
biotechnology customers, including nine of the top ten
pharmaceutical companies in the world, as measured by 2006
total revenues. For more information, please visit:
http://www.wuxipharmatech.com .
For more information, please contact:
Sherry Shao
Tel: +86-21-5046-4002
Email: pr@pharmatechs.com
2007'08.24.Fri
Avastin Approved in Europe for First-line Treatment of Patients with Advanced Lung Cancer
August 24, 2007
First Medicine Shown to Extend Survival Beyond One Year in
Previously Untreated Lung Cancer Patients
BASEL, Switzerland, Aug. 24 /Xinhua-PRNewswire/ --
Avastin (bevacizumab), Roche's innovative anti-cancer drug,
was approved today in Europe for the first-line treatment of
patients with advanced non-small cell lung cancer (NSCLC),
in combination with platinum-based chemotherapy.
NSCLC is the most common form of lung cancer, a
difficult to treat disease that kills over 3,000 people per
day worldwide.(1) NSCLC is usually diagnosed at an advanced
stage, meaning individuals diagnosed with the disease
typically have a life expectancy of only 8 to 10
months.(2),(3) Avastin is the only first-line therapy to
demonstrate improved survival benefits beyond one year in
patients with advanced NSCLC.
The approval is based on data from the pivotal US phase
III trial (E4599) and the 'Avastin in Lung' (AVAiL) phase
III trial. Both studies demonstrate that Avastin is
effective for the treatment of patients with NSCLC in
combination with platinum-based chemotherapy. The approval
is for the use of Avastin at a dose of 7.5 or 15 mg/kg, in
combination with platinum-based chemotherapy, for the
first-line treatment of patients with unresectable
advanced, metastatic or recurrent NSCLC other than
predominantly squamous cell histology. The broad label that
Avastin has received for the treatment of NSCLC allows the
combination of Avastin with any platinum-based chemotherapy
regimens (for example, together with taxanes or gemcitabine)
at the choice of the physician.
Professor Christian Manegold, Professor of Medicine at
Heidelberg
University, University Medical Center Mannheim, Germany and
Principal Investigator of the AVAiL trial, was enthusiastic
about the news: "Lung cancer is an extremely difficult
disease to treat and Avastin has proven that it can prolong
the life of patients with NSCLC. A treatment like Avastin
that breaks through the one year survival barrier is a big
step forward. The European approval for Avastin means we
can reassess our expectations for lung cancer patient
survival."
Avastin is the first and only anti-angiogenic agent
which has been shown to consistently deliver improved
overall and/or progression-free survival for patients with
colorectal, lung, breast and kidney cancer.
About the Phase III studies that formed the basis of
the approval
E4599 study
The results of the randomised, controlled, multicentre
phase III E4599 study of 878 patients with locally
advanced, metastatic or recurrent NSCLC, with histology
other than predominant squamous cell, show that median
survival of patients treated with Avastin at a dose of 15
mg/kg every three weeks plus chemotherapy was 12.3 months,
compared to 10.3 months for patients treated with
chemotherapy alone. Patients receiving Avastin in
combination with paclitaxel and carboplatin had a 25%
improvement in overall survival compared to patients who
received chemotherapy alone. Side effects were generally
manageable. Pulmonary haemorrhage/ haemoptysis cases were
observed in 2.3% of the patients receiving Avastin plus
chemotherapy. The most common adverse events associated
with Avastin therapy were: hypertension (5.6%), proteinuria
(4.2%), fatigue (5.1%) and dyspnoea (5.6%).(4)
AVAiL study
In the double-blind, randomised, controlled, phase III
AVAiL study, patients received treatment with either
Avastin at 7.5mg/kg or 15mg/kg + cisplatin/gemcitabine or
placebo + cisplatin/gemcitabine. The study involved more
than 1,000 patients world-wide with previously untreated
advanced NSCLC, with histology other than predominant
squamous cell. The results show that by adding Avastin to a
cisplatin/gemcitabine regimen progression-free survival was
significantly prolonged by 20 to 30% compared with
chemotherapy alone. No new or unexpected adverse events
were observed.
All trademarks used or mentioned in this release are
protected by law.
Additional information
-- Roche in Oncology:
http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf
-- Roche Health Kiosk, Cancer:
http://www.health-kiosk.ch/start_krebs
-- Avastin: http://www.avastin-info.com
To access video clips about Avastin, in broadcast
standard, free of charge, please go to:
http://www.thenewsmarket.com .
References
(1). Kamangar F, et al. Patterns of cancer incidence,
mortality, and prevalence across five continents: defining
priorities to reduce cancer disparities in different
geographic regions of the world. J Clin Oncol 2006;24(14):
2137-50.
(2). Schiller JH, et al. Comparison of four
chemotherapy regimens for advanced non-small-cell lung
cancer. N Engl J Med 2002;346:92-8.
(3). Sandler A, et al. Paclitaxel-Carboplatin Alone or
with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J
Med. 2006:355; 2542-50
(4). Data on file. Roche, 2006
For more information, please contact:
Roche
Erica Bersin
Email: Erica.Bersin@Roche.com
Galliard Healthcare
Dominic Elliston,
Tel: +44-207-663-2266 (direct)
Email: Delliston@galliardhealth.com
2007'08.24.Fri
Martek's life'sDHA(TM) Approved for Food Use in China
August 24, 2007
COLUMBIA, Md., Aug. 23 /Xinhua-PRNewswire/ -- Martek
Biosciences, a DHA omega-3 market leader, announced today
that the Ministry of Health in China has authorized the use
of the company's life'sDHA(TM) as a novel food ingredient.
This new designation will permit the immediate use of
Martek's life'sDHA(TM) in foods, beverages and supplements
in China for persons older than twelve months. Since 2001,
Martek's life'sDHA(TM) and life'sARA(TM) (arachidonic
acid), an omega-6 fatty acid, have been used in infant
formula throughout China.
DHA (docosahexaenoic acid) omega-3 is a long-chain
omega-3 fatty acid that serves as a primary building block
for the brain and the eyes and supports brain, eye and
cardiovascular health throughout life. There is a large and
growing body of scientific evidence demonstrating that
people of all ages, from infants to aging adults, benefit
from an adequate supply of DHA omega-3 in their diets.
Scientific reviews have noted the importance of DHA omega-3
in proper brain and eye function, and there are studies
currently underway to investigate its role in decreasing
the prevalence of certain neurological disorders.
Martek's life'sDHA(TM) is unique in the market because
it is derived from a sustainable and vegetarian source.
Made from microalgae under tightly controlled manufacturing
conditions, life'sDHA(TM) is free of oceanic contaminants
that may be present in certain fish or fish oils.
Microalgae are the only vegetarian source of DHA omega-3,
the key omega-3 for brain and eye development and function.
Martek opened a representative office in Shanghai
earlier this year. Qingdao Samuels Industrial and
Commercial Company, Ltd. has been appointed as Martek's
distributor for life'sDHA(TM) in China. Samuels will be
responsible for the selling and distribution activities
surrounding life'sDHA(TM) in food (excluding infant
formula), beverage and supplement applications in China,
Hong Kong and Macao. Additional details and contact
information for Samuels may be obtained at
http://www.samuels.cn or from Martek.
This initial approval by the Ministry of Health is part
of the regulatory process applicable to Chinese novel foods
and continues through August 5, 2009. Martek may then
apply for a final novel food certificate.
Martek Biosciences Corporation (Nasdaq: MATK) is a
leader in the innovation and development of DHA omega-3
products that promote health and wellness through every
stage of life. The company produces life'sDHA(TM), a
sustainable and vegetarian source of the omega-3 fatty acid
DHA (docosahexaenoic acid), for use in foods, beverages,
infant formula, and supplements. The company also produces
life'sARA(TM) (arachidonic acid), an omega-6 fatty acid,
from a sustainable, vegetarian source, for use in infant
formula. For more information on Martek Biosciences
Corporation, visit http://www.martek.com.
Sections of this release contain forward-looking
statements. These statements are based upon numerous
assumptions which Martek cannot control and involve risks
and uncertainties that could cause actual results to
differ. These statements should be understood in light of
the risk factors set forth in the company's filings with
the Securities and Exchange Commission, including, but not
limited to, the company's Form 10-K for the fiscal year
ended October 31, 2006 and other filed reports on Form
10-K, Form 10-K/A, Form 10-Q and Form 8-K.
For more information, please contact:
Kyle Stults
Investor Relations
Phone: +1-410-740-0081
Email: investors@martek.com
Website: http://www.martekbio.com
http://www.samuels.cn
2007'08.24.Fri
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
August 24, 2007
GAITHERSBURG, Md., Aug. 24 /Xinhua-PRNewswire/ --
MedImmune, Inc. today announced that in a Phase 3
study, motavizumab was shown to reduce hospitalizations due
to respiratory syncytial virus (RSV) by 83 percent as
compared to placebo (8.3 percent in placebo arm vs. 1.4
percent in motavizumab; p<0.001), as the trial's primary
endpoint. In addition, the trial showed a 71-percent
reduction in the incidence of RSV-specific lower
respiratory infections (LRIs) requiring outpatient
management (9.5 percent in placebo group and 2.8 percent in
the motavizumab group; p<0.001), which was a secondary
endpoint.
Motavizumab is an investigational monoclonal antibody
(MAb) being evaluated for its potential to prevent serious
disease caused by RSV in high-risk pediatric patients. This
Phase 3 trial involved 1,410 full-term infants less than six
months of age in two Native American populations. In
previous medical studies these populations were shown to
have high rates of hospitalization due to RSV.
The randomized (2:1), double-blind study was designed
to compare monthly intramuscular injections of motavizumab
against placebo. After an interim analysis conducted by an
independent data safety monitoring committee, the study was
unblinded early due to statistical evidence demonstrating
that motavizumab reduced RSV hospitalizations and LRIs
requiring outpatient medical management within this
population. Kate O'Brien, M.D., associate professor at the
Center for American Indian Health, Johns Hopkins Bloomberg
School of Public Health, served as the study's principal
investigator.
"We are pleased with the results of this study
which support the positive results seen in our Phase 3
pivotal trial comparing motavizumab and Synagis(R)
(palivizumab) that were previously reported at the
Pediatric Academic Societies meeting in May 2007,"
said Genevieve Losonsky, M.D., vice president, clinical
development, infectious disease, MedImmune.
Motavizumab was well tolerated in these Native American
infants, with an overall incidence and severity of adverse
events (AEs) that were similar between the motavizumab and
the placebo groups. The mortality rates were not
statistically different between groups (0.4 percent in the
placebo arm, n=2 and 0.3 percent in the motavizumab arm,
n=3) and were not considered to be related to the study
drug. As was suggested in the pivotal Phase 3 trial
conducted in high-risk, preterm infants, rates of
hypersensitivity related skin rashes within two days of
dosing were seen in about one percent of treated children
in the motavizumab group.
MedImmune's Commitment to RSV Prevention
MedImmune is a world leader in the development of
innovative therapeutic biologic products to prevent RSV
disease. In 1996, MedImmune launched the first anti-RSV
drug, RespiGam(R) (respiratory syncytial virus immune
globulin intravenous (human) (RSV-IGIV)), which was a
polyclonal antibody administered via four-hour intravenous
infusion. In 1998, MedImmune introduced Synagis, which was
a significant product improvement as a monthly intramuscular
injection for the prevention of severe RSV, as well as being
the first MAb to receive U.S. Food and Drug Administration
(FDA) approval for an infectious disease. With the
development of motavizumab, MedImmune continues to
reinforce its commitment to developing anti-RSV products.
In a head-to-head comparative Phase 3 trial with Synagis,
motavizumab met its primary endpoint of reducing
RSV-related hospitalizations in high-risk pediatric
patients and met its secondary endpoint of reducing
medically attended, outpatient respiratory tract infections
in that patient group. MedImmune is also developing a
small-molecule product candidate to prevent RSV as well as
a vaccine against RSV, both of which are in Phase 1
clinical trials.
About RSV
Each year, up to 125,000 infants in the U.S. are
hospitalized with severe RSV infections, the leading cause
of lower respiratory tract infections in infants in the
United States. RSV is the most common respiratory infection
in infancy or childhood. Approximately one-half of all
infants are infected with RSV during the first year of
life, and nearly all children have been infected at least
once by the time they reach their second birthday. Children
born prematurely as well as those with chronic lung disease
(CLD) or congenital heart disease (CHD) are at highest risk
for severe disease and hospitalization due to RSV. The virus
may also cause severe illness in other high-risk groups such
as the elderly, those with underlying respiratory or cardiac
disease, and those with compromised immune systems (e.g.,
bone marrow transplant patients).
About Motavizumab
Motavizumab, formerly known as Numax(R), is an
investigational humanized MAb being evaluated for its
potential to prevent serious lower respiratory tract
disease caused by RSV in pediatric patients at high risk of
RSV disease. Phase 1 and Phase 2 study data have been
reported showing that motavizumab appears to have a similar
safety and pharmacokinetic profile to Synagis in infants.
Additionally, in early phase studies children treated with
motavizumab had reduced RSV replication in the upper
respiratory tract. In its first pivotal trial, which was a
head-to-head comparative trial with Synagis, motavizumab
demonstrated a 26-percent reduction in RSV hospitalizations
due to RSV and a 50-percent reduction in the incidence of
RSV lower respiratory tract infections requiring outpatient
management, its secondary endpoint.
About Synagis
Synagis is the only monoclonal antibody approved by the
FDA to help prevent an infectious disease. Synagis was
approved for use in the United States in 1998, Europe in
1999, and Japan in 2002. Synagis is currently available in
62 countries.
Synagis is indicated for the prevention of serious
lower respiratory tract disease caused by respiratory
syncytial virus (RSV) in pediatric patients at high risk of
RSV disease and is administered by intramuscular injection.
The safety and efficacy of Synagis were established in
infants with bronchopulmonary dysplasia (BPD), infants with
a history of prematurity (less than or equal to 35 weeks
gestational age), and children with hemodynamically
significant congenital heart disease. The first dose of
Synagis should be administered prior to commencement of the
RSV season, which usually starts in the fall and runs
through the spring. Patients, including those who develop
an RSV infection, should continue to receive monthly doses
throughout the season.
Very rare cases (<1 per 100,000 patients) of
anaphylaxis and rare (<1 per 1,000 patients)
hypersensitivity reactions have been reported with Synagis.
Cases of anaphylaxis were reported following re-exposure to
Synagis and rare severe hypersensitivity reactions occurred
on initial exposure or re-exposure. If a severe
hypersensitivity reaction occurs, therapy with Synagis
should be permanently discontinued. If milder
hypersensitivity reaction occurs, caution should be used on
re-administration of Synagis.
In clinical trials, the most common adverse events
occurring at least one percent more frequently in
Synagis-treated patients than controls were upper
respiratory infection, otitis media, fever and rhinitis.
Cyanosis and arrhythmia were seen in children with CHD.
The pivotal trial for Synagis was called the IMpact
trial and comprised a total of 1,502 children who were
randomized (500 placebo, 1,002 Synagis) in a double-blind,
placebo-controlled protocol where 1,486 children completed
the study's follow-up.
In the IMpact trial, monthly prophylaxis with Synagis
via intramuscular injections was associated with a
55-percent reduction in hospitalization as a result of RSV
(p=<0.001). Reductions were observed in both children
with bronchopulmonary dysplasia (38 percent reduction) and
premature children without BPD (78 percent reduction).
Approximately 50 percent of the children in the analysis
had BPD.
For full prescribing information for Synagis, see the
company's website at:
http://www.medimmune.com/products/synagis/index.asp .
About International RSV Prophylaxis
Outside the United States, Synagis is distributed by
Illinois-based Abbott, a global, broad-based health care
company. Abbott also has the ex-U.S. distribution rights
to motavizumab.
About MedImmune, Inc.
MedImmune strives to provide better medicines to
patients, new medical options for physicians and rewarding
careers to employees. Dedicated to advancing science and
medicine to help people live better lives, the company is
focused on the areas of infectious diseases, cancer and
inflammatory diseases. With approximately 3,000 employees
worldwide and headquarters in Maryland, MedImmune is wholly
owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more
information, visit MedImmune's website at
http://www.medimmune.com .
For more information, please contact:
Media -
Tor Constantino
MedImmune, Inc.
Tel: +1-301-398-5801
Investors -
Peter Vozzo
MedImmune, Inc.
Tel: +1-301-398-4358
2007'08.24.Fri
Media Invitation: Are You Ready for the Next Chapter in Lung Cancer Care?
August 24, 2007
LONDON, Aug. 23 /Xinhua-PRNewswire/ -- Ready for Fresh
Perspectives on Mutational Research, Future Treatment
Prospects in Non-Small-Cell Lung Cancer (NSCLC) and a
Milestone Announcement From Boehringer Ingelheim?
Learn more at the upcoming international media webcast,
'The second generation -- revealing the next chapter in the
evolution of lung cancer care' coinciding with the 12th
World Conference on Lung Cancer.
Available on-line 6 September 2007.
Find out more!
Visit http://www.lungcancer-thenextchapter.com to
register.
For more information, please visit:
Claire Pope of Ogilvy Healthworld for Boehringer
Ingelheim
Phone: +44-207-108-8686
Email: claire.pope@ogilvyhealthworld.com
Website: http://www.lungcancer-thenextchapter.com
2007'08.24.Fri
Acision Increases Messaging Capacity for PTML by 700%
August 23, 2007
ISLAMABAD, Pakistan, Aug. 23 /Xinhua-PRNewswire/ --
Acision today announces that following a competitive
tender, leading Pakistani operator Pak Telecom Mobile
Limited (PTML) has upgraded its Acision high performance
Short Message Service Centre (SMSC) to support rapid uptake
of SMS for its mobile service brand, Ufone. PTML is
expanding Ufone's messaging capacity by 700% to handle very
high volumes of messaging traffic and provide subscribers
with a consistently high-quality messaging experience.
The mobile market in Pakistan has been experiencing
strong and sustained development, reaching above 60 million
subscribers across the country, while still only at a 40%
penetration level. In Pakistan's unsaturated market which
is experiencing falling handset costs, there are a high
number of new subscribers to compete for, with most
operators adding an average of half a million subscribers
per month. However as penetration levels rise, mobile
operators will have to differentiate on superior service
levels if they are to avoid simply competing on price.
PTML's SMSC extension will provide the operator with a
state-of-the-art messaging platform to meet the growing
demand for SMS messaging among mobile phone users in
Pakistan. Building on an already established relationship
with
Acision as a key messaging infrastructure provider, PTML
can rely on its high performance SMSC to scale ahead of
growing demand and to bring continuous innovation,
anticipating future messaging requirements.
Mr Mubashir Naqvi, President and CEO for PTML
commented: "There is real opportunity for operators in
Pakistan to grow subscriber bases, but to successfully build
long-term success it is crucial to have a reliable and
advanced infrastructure in place. Acision has provided
quality and innovation in messaging platforms over the past
six years, establishing the company as
PTML's preferred value-added services provider.
Boudewijn Pesch, Managing Director for Acision in Asia
Pacific, added:
"Pakistan is an exciting market for Acision,
presenting great potential for high performance mobile data
services such as mobile messaging, which operators are
looking to build on as they seek to capture forecasted
revenues. In Pakistan, Acision powers messaging systems for
three out of six mobile operators and globally we process
half of all text and multimedia messages sent daily. This
means that we have not only the experience, presence and
support capability to meet PTML's requirements for today,
but also for its future long-term growth."
Notes to Editors
About Acision
Established in June 2007, Acision launched with more
than 300 clients, serving over one billion customers
worldwide. Renowned for its progressive, exciting and agile
philosophy of innovation along with assured service
delivery, Acision enables network operators, service
providers, broadband operators and content owners to
increase revenues, enhance customer loyalty and capitalise
on the opportunities offered by convergence. With over 43
years of experience, Acision leads the market in Intuitive
Messaging, Intelligent Charging, Content Enablement and
Customer Intelligence Management. Acision is the partner of
choice in high volume mobile data services with over 50 per
cent of global messaging traffic generated through its
platforms.
Acision was formed following the purchase of
LogicaCMG's Telecoms
Products business for GBP265m (US $525m), by a consortium
led by Atlantic
Bridge Ventures and Access Industries. The company employs
approximately
1,700 people in 22 countries across six continents, and
launched as a half billion US dollar company. More
information is available at
http://www.acision.com
About Ufone
Ufone is an Etisalat Group Company and is Pakistan's
second largest cellular operator.
The company's customer base has now crossed 14 million.
Ufone service is scattered in more than 2,500 cities, towns,
villages and headquarters. The company employs more than
2,200 people. The company operates with a franchise network
of 300 plus and 25 company-owned customer service centres
along with a distribution network of 150,000 outlets across
Pakistan.
For more information, please contact:
Radha K Raman
Tel: +65-6415-7840
Email: radha.raman@acision.com
Kevin Foo / Rani Ramaya
Upstream Asia
Tel: +65-6323-7377
Email: acision@upstreamasia.com
Scott Allen
Global Marketing Director, Acision
Tel: +44-118-965-9200
Email: scott.allen@acision.com
David Ross Tomlin / Bettina Winters
Hotwire PR
Tel: +44-207-608-2500
Email: acision@hotwirepr.com
2007'08.24.Fri
Microsoft to Provide Retrofit for Xbox 360 Wireless Racing Wheel
August 23, 2007
Action is precautionary and voluntary following reports of
component malfunction.
REDMOND, Wash., Aug. 23 /Xinhua-PRNewswire/ --
Microsoft Corp today announced that it is taking a
precautionary measure and voluntarily providing customers
with a free retrofit to the Xbox 360(TM) Wireless Racing
Wheel.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO )
The action is being taken after Microsoft was informed
of a very small number of incidents of a malfunction in the
Xbox 360 Wireless Racing Wheel, in which a component in the
wheel chassis may overheat and release smoke when the AC/DC
power supply is used to energise the wheel. There have been
no reported incidences of fire, personal injury or property
damage resulting from the component failure in the wheel.
Owners of the Xbox 360 Wireless Racing Wheel should
stop using the AC/DC power supply until they have obtained
their retrofit. They may continue to operate the wheel
using battery power.
Owners of the Xbox 360 Wireless Racing Wheel should
visit http://www.xbox.com/support or within the US, US
territories and Canada call Microsoft at +1 (800) 4MY-XBOX
(469-9269) to register for the free retrofit and protect
against the potential hazard described above. Instructions,
if necessary, will be provided with the retrofit. Microsoft
is notifying and will be coordinating its response
activities with the relevant regulatory agencies such as
the U.S. Consumer Product Safety Commission. This may
affect delivery dates.
About Xbox 360
Xbox 360 is a superior video game and entertainment
system delivering the best games, unique entertainment
features and a unified online gaming network that revolve
around gamers. Xbox 360 will have a portfolio of more than
300 games and will be available in nearly 40 countries by
the end of 2007. More information can be found online at
http://www.xbox.com/xbox360.
About Microsoft
Founded in 1975, Microsoft (Nasdaq: MSFT) is the
worldwide leader in software, services and solutions that
help people and businesses realise their full potential.
About Microsoft EMEA (Europe, Middle East and Africa)
Microsoft has operated in EMEA since 1982. In the
region Microsoft employs more than 12,000 people in 60
subsidiaries, delivering products and services in 138
countries and territories.
This material is for informational purposes only.
Microsoft Corp disclaims all warranties and conditions with
regard to use of the material for other purposes. Microsoft
Corp shall not, at any time, be liable for any special,
direct, indirect or consequential damages, whether in an
action of contract, negligence or other action arising out
of or in connection with the use or performance of the
material. Nothing herein should be construed as
constituting any kind of warranty.
NOTE TO EDITORS: If you are interested in viewing
additional information on Microsoft in EMEA, please visit
http://www.microsoft.com/emea or the EMEA Press Centre at
http://www.microsoft.com/emea/presscentre. Web links,
telephone numbers and titles were correct at the time of
publication, but may since have changed. For additional
assistance, journalists and analysts may contact the
Microsoft EMEA Press Office at +44 870 243 0515 or other
appropriate contacts listed at
http://www.microsoft.com/emea/contactus.
If you are interested in viewing additional information on
Microsoft Corp, please visit the Microsoft web page at
http://www.microsoft.com/presspass on Microsoft's corporate
information pages.
For more information, please contact:
Microsoft
David Dennis
Tel: +1-425-706-0433
Email: ddennis@microsoft.com
Edelman
Jennifer Poulson
Tel: +81-3-6403-5212
Email: jennifer.poulson@edelman.com
Sara Campbell
Tel: +1-323-857-9100
Email: sara.campbell@edelman.com
2007'08.24.Fri
Chinese Initial Public Offering Indicator: IPO Indicator up 13% as Mainland Stock Market Reaches Record High
August 23, 2007
SHANGHAI, China, Aug. 23 /Xinhua-PRNewswire/ --
July 2007: 287.8
June 2007: 254.3
Month-to-month change: 13.2%
July 2006: 177.9
Year-to-year change: 61.7%
Click
http://www.xinhuafinance.com/en/charts/ipo_rpi/0708/ipo_chart0708.jpg
to download the chart.
(Logo: http://www.xprn.com/xprn/sa/200702151700.gif )
Highlights
The IPO indicator reached a new high of 287.8 at the
end of July, a 13.2 percent increase from June. Six stocks
were added to the indicator, and five were removed,
bringing the total to 113.
Analysis
Of the 107 equities included in both the June and July
indicators, ninety-seven increased in price and ten fell.
Banking sector stocks accounted for 50 percent of the
increase in the indicator's market capitalization, while
two telecom services stocks, China Communications Services
(H share, 0552) and Guomai Technologies (A share, 002093),
accounted for 40 percent of the decrease. China Coal (H
share, 1898) contributed to 11.5 percent of the indicator's
increase. The Industrial and Commercial Bank of China (ICBC;
A share, 601398; H share, 1398), which went public last
October, now has the largest market capitalization among
all banks worldwide.
Methodology
A stock's float-adjusted market capitalization over
time forms the basis for indicator calculations. Stock
dividends, stock splits, special dividends, share
consolidations, repurchases, spin-offs, and combination
stock distributions may trigger adjustments to the
indicator values. Only companies incorporated and domiciled
in mainland China that go public on the Shanghai, Shenzhen,
and Hong Kong stock exchanges are included. Companies are
removed from the indicator after twelve months.
Xinhua Finance/Milken Institute China Indicators
The Xinhua Finance/Milken Institute China Indicators
provide investors, analysts, and financial professionals
insight into China's money and capital markets. Five of the
eight indicators have been launched since November 2006: the
Renminbi Pressure Indicator, the Chinese IPO Indicator, the
Market Adjusted Debt (MAD) Indicator, the Banking Strength
Indicator (BSI), and the Adjusted Trade and Finance (ATF)
Indicator. The remaining three indicators (the China
M&A Indicator, the China Privatization Indicator, and
the China Corporate Governance Indicator) will be launched
later this year.
Period Coverage and Frequency
New companies are added to the indicator as soon as
they are listed, while current companies are removed after
twelve months. The IPO Indicator has a base date of
December 31, 1997, when the indicator's value was set equal
to 100, and covers the period from December 31, 1991, to the
present. Values are calculated on a monthly basis. The
indicator for each month is released in the third week of
the following month.
Sources of Data
The real-time and historical trading data used in the
construction of this indicator are provided by Bloomberg
and Xinhua Finance; underlying information used to
calculate the float ratio is obtained from a variety of
sources, including Xinhua Finance's subsidiary Mergent,
stock exchanges, regulators, and the companies themselves.
Corporate actions are sourced from Xinhua Finance,
regulatory filings, and news services.
To view additional information, visit
http://www.xinhuafinance.com/indicators and
http://www.milkeninstitute.org/chinaindicators .
Xinhua Finance Limited ("XFL") is China's
premier financial information and media service provider
and is listed on the Mothers Board of the Tokyo Stock
Exchange (symbol: 9399) (OTC ADRs: XHFNY). Bridging China's
financial markets and the world, Xinhua Finance's
proprietary content platform, comprising Indices, Ratings,
Financial News, and Investor Relations, serves financial
institutions, corporations and re-distributors worldwide.
Through its subsidiary Xinhua Finance Media Limited
(Nasdaq: XFML), XFL leverages its content across multiple
distribution channels in China including television, radio,
newspaper, magazine and outdoor media. Founded in November
1999, XFL is headquartered in Shanghai, with offices and
news bureaus spanning 11 countries worldwide. For more
information, please visit http://www.xinhuafinance.com .
The Milken Institute is a nonprofit, independent
economic think tank whose mission is to improve the lives
and economic conditions of diverse populations around the
world by helping business and public policy leaders
identify and implement innovative ideas for creating
broad-based prosperity. The Milken Institute has extensive
expertise in China and conducts ongoing research on China's
banking and capital markets. It is based in Santa Monica,
Calif. For more information, please visit
http://www.milkeninstitute.org .
Contact information:
Xinhua Finance
China
Ms. Joy Tsang
Tel : +86-21-6113-5999, +852 948 64363
Email : joy.tsang@xinhuafinance.com
Mr. Scott Zhang
Tel : +86-21-6113-5996
Email : scott.zhang@xinhuafinance.com
Taylor Rafferty (Media contact for Xinhua Finance)
Japan
Mr. James Hawrylak
Tel : +81-3-5733-2621
Email: James.hawrylak@taylor-rafferty.com
United States
Mr. John Dudzinsky
Tel : +1-212-889-4350
Email: John.Dudzinsky@taylor-rafferty.com
Europe
Faisal Kanth
Tel : +44-20-7614-2900
Email : Faisal.Kanth@taylor-rafferty.co.uk
Milken Institute
Ms. Jennifer Manfre
Associate Director of Communications
Tel : +1-310-570-4623
Email : jmanfre@milkeninstitute.org
2007'08.24.Fri
Fiction, Comics, Science, and More: Berlin Partner to Promote the Berlin Publishing Industry in Beijing
August 23, 2007
BERLIN, Aug. 23 /Xinhua-PRNewswire/ -- Berlin Partner
is set to present Berlin as a publishing capital at the
Beijing International Bookfair from August 30 - September
3, 2007 in Beijing. Berlin Partner and its sister
organization from North Rhine-Westfalia will be the only
German state business development agencies represented at
the fair.
Berlin is one of the most important publishing cities
in Germany and even leads the nation in fiction, science,
and educational publishing. The capital is home to 500
printing presses and boasts 150 companies specializing in
the processing of printed material, including bookbinding
and special embossment. With 8,400 first editions (2005),
Berlin ranks second of all publishing cities in Germany.
The capital produces 11 daily newspapers, 3 Sunday papers,
10 city magazines, 7 advertising papers, 6 weekly papers,
as well as a wide variety of regional and national
magazines and tender papers. There are roughly 13,200
people working in the print industry in Berlin, which last
year recorded a turnover of 3.8 million euro.
To mark the occasion, Berlin Partner will issue a
brand-new Chinese language brochure profiling Berlin's
print and publishing industry. The brochure will also
feature information on Berlin Partner services available to
Chinese publishers, including the establishment of contacts
with Berlin publishers, libraries, and decision-makers, as
well as organization of business trips to Berlin.
The Berlin stand will present more than 50 books on
Berlin. In addition, Klaus Baumgart, creator of the
children's book "Laura's Star" and the most
successful children's writer in Germany today, will attend
the fair and provide support for Berlin Partner's efforts.
"Laura's Star" has already been filmed by Cartoon
Film, one of Berlin's most prominent animation companies,
and was also adapted for TV by a German-Chinese
co-production. Berlin Partner will also draw on the support
of another Berliner, Jutta Harms, a prominent organisor of
international comic festivals and an expert on the European
comic industry.
For more Chinese-language information on business in
Berlin visit:
http://www.businesslocationcenter.de/cn/Start/seite0.jsp
and: http://www.berlin-china.net
For more information on the German stand at the Beijing
International Bookfair visit:
http://www.peking-bookfair.german-pavilion.com/gp/peking2007/home/index.cfm
For more information, please contact:
Berlin Partner GmbH
Ludwig Erhard Haus
Fasanenstrasse 85
D-10623 Berlin
http://www.berlin-partner.de
Christoph Lang
Head, Press and Public Relations
Tel: +49-30-39980-123
Fax: +49-30-39980-113
Mobile: +49-1577-3998-123
Email: Christoph.Lang@berlin-partner.de
2007'08.24.Fri
International Spread of Disease Threatens Health, Economies and Security
August 23, 2007
World Health Report 2007: A safer future -- global public
health security in the 21st century
GENEVA, Switzerland, Aug. 23 /Xinhua-PRNewswire/ --
More than at any previous time in history, global public
health security depends on international cooperation and
the willingness of all countries to act effectively in
tackling new and emerging threats. That is the clear
message of this year's World Health Report, A Safer Future,
which concludes with six key recommendations to secure the
highest level of global public health security:
(Logo:
http://www.xprn.com/xprn/sa/20061102095006-51-min.jpg )
-- Full implementation of the revised International
Health Regulations
(IHR 2005) by all countries.
-- Global cooperation in surveillance and outbreak
alert and response.
-- Open sharing of knowledge, technologies and
materials, including
viruses and other laboratory samples, necessary to
optimize secure
global public health.
-- Global responsibility for capacity building within
the public health
infrastructure of all countries.
-- Cross-sector collaboration within governments.
-- Increased global and national resources for
training, surveillance,
laboratory capacity, response networks, and
prevention campaigns.
In our increasingly interconnected world, new diseases
are emerging at an unprecedented rate, often with the
ability to cross borders rapidly and spread. Since 1967, at
least 39 new pathogens have been identified, including HIV,
Ebola haemorrhagic fever, Marburg fever and SARS. Other
centuries-old threats, such as pandemic influenza, malaria
and tuberculosis, continue to pose a threat to health
through a combination of mutation, rising resistance to
antimicrobial medicines and weak health systems.
"Given today's universal vulnerability to these
threats, better security calls for global solidarity,"
said Dr Margaret Chan, Director-General of the World Health
Organization (WHO). "International public health
security is both a collective aspiration and a mutual
responsibility. The new watchwords are diplomacy,
cooperation, transparency and preparedness."
The need for global solidarity is especially clear in
the response to outbreaks of infectious diseases. This
month, WHO has been closely involved in the response to an
outbreak of Marburg fever in Uganda. Together with partners
in the Global Outbreak Alert and Response Network (GOARN)
including the United States Centers for Disease Control and
Prevention (CDC), Medecins sans Frontieres, the Uganda Virus
Research Institute, and African Field Epidemiology Network
and local NGOs, WHO is supporting the Ministry of Health to
strengthen active surveillance, contact tracing, infection
control, logistics, and social mobilization activities in
an effort to contain the outbreak.
The team is carefully studying conditions surrounding
the initial transmission, in the hope of improving
understanding of where the virus resides in nature and how
it passes to humans, improving the ability to predict and
prevent outbreaks in the future.
WHO and its partners are closely involved in the global
response to H5N1 avian influenza, which has caused huge
outbreaks in poultry and at least 308 human deaths since it
was first isolated in humans in 1997.
This World Health Report traces the history of efforts
to contain infectious diseases (including plague, cholera
and smallpox). It describes the evolution of outbreak
surveillance and response activities of international
partnerships of agencies and technical institutions. These
include GOARN, the chemical and environmental health
incident alert and response system, and the Global Polio
Eradication Initiative, which is supporting surveillance of
many other vaccine-preventable diseases.
The report shows how and why diseases are increasingly
threatening global public health security. High and rapid
mobility of people is one factor. Airlines now carry more
than 2 billion passengers a year, enabling people and the
diseases that travel with them to pass from one country to
another in a matter of hours. The potential health and
economic impact was seen in 2003 with SARS, which cost
Asian countries an estimated US$ 60 billion of gross
expenditure and business losses.
The report outlines some of the human factors behind
public health insecurity, including:
-- inadequate investment in public health resulting
from a false sense
of security in the absence of infectious disease
outbreaks;
-- unexpected policy changes such as a decision
temporarily to halt
immunization in Nigeria, which led to the
re-emergence of polio cases;
-- conflict situations when forced migration obliges
people to live
in overcrowded, unhygienic and impoverished
conditions heightening
the risk of epidemics;
-- microbial evolution and antibiotic resistance; and
-- animal husbandry and food processing threats such as
the human form
of bovine spongiform encephalopathy (BSE) and Nipah
virus.
Pandemic influenza is described as the most feared
threat to health security in our times. The report sets out
the WHO strategic action plan to respond to a pandemic,
draws attention to the need for stronger health systems and
for continued vigilance in managing the risks and
consequences of the international spread of polio and the
newly emerging strain of extensively drug-resistant TB
(XDR-TB). New health threats have also emerged, linked to
potential terrorist attacks, chemical incidents and
radionuclear accidents.
The revised International Health Regulations (2005) are
based on the premise that no country can fully protect its
citizens in isolation or through traditional border
controls. The IHR 2005 is a set of rules that governs how
countries should assess and report to WHO public health
emergencies of potential international concern. The broad
definitions of "public health risk",
"disease" and "event" ensure that risks
caused by the accidental or intentional release of pathogens
or chemical or radionuclear materials are covered by the
Regulations.
Since the IHR 2005 entered into force, almost all of
the 193 WHO Member States have established their national
IHR focal points, with 179 designations. Since then, WHO
has been receiving alerts of health events on a regular
basis, conducting joint risk assessments with the notifying
State(s) and sharing real-time information with other Member
States.
The full report can be downloaded at :
http://www.who.int/whr/2007/en/
The Report is available in English, French and Spanish
and the Executive summery in the six UN languages.
All press releases, fact sheets and other WHO media
material may be found at: http://www.who.int .
For further information please contact:
Fadela Chaib
WHO Department of Communications, Geneva
Tel: +41 22 791 32 28
Cell: +41 79 475 55 56
Email: chaibf@who.int
Iain Simpson
WHO Department of Communications, Geneva
Tel: +41 22 791 32 15
Cell: +41 79 475 55 34
Email: simpsoni@who.int
Thomson Prentice
Editor World Health Report
Tel: +41 22 791 42 24
Cell: +41 79 244 60 30
Email: prenticet@who.int
2007'08.24.Fri
Bank of America Makes Investment in Countrywide Financial
August 23, 2007
Buys convertible preferred stock for $2 billion
CHARLOTTE, N.C., Aug. 23 /Xinhua-PRNewswire/ -- Bank of
America Corporation today announced it has made an
investment in Countrywide Financial Corporation, the
largest mortgage lender in the United States.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20050720/CLW086LOGO-b )
Bank of America will invest $2 billion in the form of a
non-voting convertible preferred security yielding 7.25
percent annually. The security can be converted into common
stock at $18 per share.
"We believe that in the current turmoil the stock
market has been underestimating the value in Countrywide's
operations and assets," said Kenneth D. Lewis, Bank of
America chairman and chief executive officer. "This
investment reflects our confidence in their business and
recognizes the importance of the company in providing home
financing across the country. We hope this investment will
be a step toward a return to more normal liquidity in the
mortgage markets. Countrywide has a strong mortgage
origination business and it services the mortgages of one
in seven American households."
Bank of America
Bank of America is one of the world's largest financial
institutions, serving individual consumers, small and middle
market businesses and large corporations with a full range
of banking, investing, asset management and other financial
and risk-management products and services. The company
provides unmatched convenience in the United States,
serving 57 million consumer and small business
relationships with more than 5,700 retail banking offices,
more than 17,000 ATMs and award-winning online banking with
more than 22 million active users. Bank of America is the
No. 1 overall Small Business Administration (SBA) lender in
the United States and the No. 1 SBA lender to minority-owned
small businesses. The company serves clients in 175
countries and has relationships with 98 percent of the U.S.
Fortune 500 companies and 80 percent of the Fortune Global
500. Bank of America Corporation stock (NYSE: BAC) is
listed on the New York Stock Exchange.
http://www.bankofamerica.com
For more information, please contact:
Investors:
Kevin Stitt
Bank of America
Tel: +1-704-386-5667
Lee McEntire,
Bank of America
Tel: +1-704-388-6780
Leyla Pakzad
Bank of America
Tel: +1-704-386-2024
Media:
Scott Silvestri
Bank of America
Tel: +1-704-604-8567
Email: scott.silvestri@bankofamerica.com
2007'08.24.Fri
Maria Sharapova Defends US Open Title in New York Style
August 23, 2007
Sharapova Unveils Custom Day and Evening Dresses Designed
to Match Her Explosive Play and Iconic On-Court Style
NEW YORK, Aug. 23 /Xinhua-PRNewswire/ --
Today on the rooftop of Rockefeller Center, Maria
Sharapova showed why New York is a magical place for her as
she unveiled her 2007 US Open day and evening dresses she'll
wear for match play. One of the world's most dynamic
cities, New York is a venue where the tennis star proved
today she could indulge in her love of fashion and sense of
style while making a powerful statement on the court. The
defending champion joined Nike designers for a press
conference to debut her custom, atomic red,
Swarovski-crystal encrusted evening dress she'll take to
the court in for her first round match. She modeled the
flared, shift-silhouette dress set against the backdrop of
the New York City skyline that inspired its design. She
also presented a custom white and black version she'll wear
for day matches.
( Logo:
http://www.newscom.com/cgi-bin/prnh/19990818/NIKELOGO )
Last year, Sharapova began solidifying her iconic
approach to performance and style by taking on-court wear
to a new level by competing in custom dresses designed
specially for her day and evening matches. Best known at
last year's tournament for the "little black
dress" she wore for evening matches, Maria sent a
clear message about her style while on her way to winning
the 2006 title. Continuing the trend for this year's US
Open, Maria will turn heads again in new custom outfits
that showcase her impeccable sense of style while
incorporating cutting-edge technical features, allowing her
to perform at her very best.
Building on the success of their past collaborations,
Nike and Maria worked together for the 2nd time,
specifically for the US Open to create coordinated tennis
outfits for day and night matches that seamlessly blend
beauty and performance. "Nike has always understood my
desire to make a big impression in New York," says
Maria. "And the dresses that we've worked on for the
US Open have always looked as good as they feel when I'm
playing. This year is especially exciting because the
designs are inspired by the city itself. "
For Nike Head of Global Tennis Apparel Gill Brown,
working with Maria was an opportunity to design apparel for
an athlete whose fashion instinct is as refined as her game:
"She is dedicated to tennis and shows the same amount
of passion for her apparel -- a real perfectionist,"
says Gill. "For the US Open, our challenge was to
design a look that connects Maria to New York and will be
special to her. The answer is the skyline graphic, which
links the day and night dress together in a very dramatic
way."
New York by Night
For Maria's night matches, designers worked with her to
create a
knee-length atomic red dress with a simple, flared shift
silhouette in ultra lightweight Dri-FIT jersey. The
Dri-FIT fabrication is elegant and sleek, delivering a
fluid silhouette, ease of movement, moisture management,
and breathability. No-sew constructed seams throughout not
only provide a clean finish to the dress, but also
guarantee minimum abrasion and maximum comfort.
In addition to its feminine detailing, the dress is
done in an atomic red hue, a striking element that stands
out as powerfully as her forehand. The tennis star played
a big part in selecting the right shade, innately aware of
which color would best enhance the style she wanted for
this tournament and what it might symbolize. Red, after
all, is the color closely associated with the Big Apple,
from the carpets during fashion week to the twinkling
taillights on 5th Avenue at night. After winning in New
York last year, red seemed the most appropriate color for
Maria to make her red carpet return to the tournament.
Knowing Maria's affinity for the energy and glamour of
New York, Nike integrated New York's famous skyline into
the dress, thereby artfully uniting her game with her
favorite city. Maria's evening dress literally and
figuratively reflects the backdrop of the city at night.
The front graphic design is patterned after the skyline
with an abstract twist as the design is inverted and
featured upside down. By incorporating more than 600
authentic Swarovski crystals, the result is a stunning
neckline worthy of any red carpet appearance. The New York
skyline is represented in the night dress by more than 600
Swarovski crystals, creating the stunning night skyline of
one of the fashion capitals of the world. Three crystal
buttons down the back create a triple keyhole effect that
offers ventilation and an attractive,
functional-yet-stylish appearance.
New York by Day
For Maria's day matches, designers worked with her to
create a classic black and white dress with a simple,
flared shift silhouette also done in an ultra lightweight
Dri-FIT jersey. The outfit is enhanced with feminine
detailing such as an upper body and overlay hem in
transparent Dri-FIT jersey. Dramatic elements like the
stunning graphics on the front -- that offers a similar
interpretation of the New York skyline flipped on the
inverse -- and a sexy scooped back neckline appeal to
Maria's aesthetic sensibility.
Designers also integrated New York's famous skyline
into the day dress. Both aesthetic and functional, the
abstract graphic -- depicting the inverted, angular shapes
of Manhattan's towering buildings and shadows -- adorns the
transparent fabric of the upper body. By using a laser-cut,
heat bonded self fabric and a highly contrasting color
combination, Nike has transformed this notorious landscape
into a striking, negative-print effect.
These kinds of dramatic visual touches, along with
unexpected elements like a sexy scooped-back neckline,
appeal to both Maria's aesthetic and athletic
sensibilities.
"Details such as these that are extremely
important to Maria," says senior designer Colleen
Sandieson. "Not only do they make her feel special,
but they also help enhance her performance." The
scoop-back design not only facilitates movement, but also
creates a flattering appearance that rivals current runway
looks. Again, Dri-FIT fabrication delivers a fluid
silhouette, ease of movement, moisture management, and
breathability. The no-sew constructed seams offer minimum
abrasion with maximum comfort. With its color-block
palette of black and white, the day dress is the epitome of
simplicity, beauty, and athletic elegance. Atomic red,
seamless shorts inject an added flash of color for an
eye-catching finish.
The Venue
The fourth of the 2007 Grand Slam tournaments, the US
Open will take place August 27th - September 8th in New
York. Tune in as Maria models (by playing in) the dress she
inspired, resetting the boundary where beauty and
performance meet.
EVENT / MARIA IMAGERY AVAILABLE FROM 7pm ET:
ftp://ftp.gcigroup.com/ Login: Nike Password:
sharapova
ABOUT NIKE, INC. (NYSE: NKE)
Based near Beaverton, Oregon is the world's leading
designer, marketer and distributor of authentic athletic
footwear, apparel, equipment and accessories for a wide
variety of sports and fitness activities. Wholly owned Nike
subsidiaries include Converse Inc., which designs, markets
and distributes athletic footwear, apparel and accessories;
NIKE Bauer Hockey Inc., a leading designer and distributor
of hockey equipment; Cole Haan, which designs, markets, and
distributes fine dress and casual shoes and accessories;
Hurley International LLC, which designs, markets and
distributes action sports and youth lifestyle footwear,
apparel and accessories and Exeter Brands Group LLC, which
designs and markets athletic footwear and apparel for the
value retail channel.
For more information, please contact:
Nike Media Relations
Tel: +1-212-367-4447
Website: http://www.nikebiz.com
2007'08.24.Fri
Leading Anti-Money Laundering Organization Launches First Compensation Survey for the Industry
August 23, 2007
Survey to Collect Data from Professionals in Financial
Institutions,
Law Enforcement and Regulatory Agencies Worldwide
MIAMI, Aug. 22 /Xinhua-PRNewswire/ -- The Association
of Certified Anti-Money Laundering Specialists (ACAMS), the
premier membership organization for AML professionals, today
launched the first salary survey designed specifically for
the AML/CFT (combating the financing of terrorism)
industry. Administered through an independent, third-party
research firm, the "2007 AML/CFT Compensation
Survey" was released today to specialists in law
enforcement, financial institutions, and government
regulatory agencies worldwide. The survey's results report
is expected in October 2007.
In an industry with thousands of specialists around the
world, a primary goal of the survey is to collect and
analyze salary data from a comprehensive range of public
and private sector employees in the AML/CFT field at every
level. Participants in the survey will range from
professionals in community banks to executives at global
financial institutions, as well as representatives from law
enforcement and in regulatory agencies on six continents.
"As an instrumental global AML resource center,
ACAMS is spearheading the effort to train and support
professionals in the face of increasing demand for AML
specialists," says Gregory Calpakis, Executive
Director for ACAMS. "The compensation survey will be a
valuable tool for the field's rapidly growing number of
practitioners, who have long awaited this kind of
aggregated, comprehensive information."
As members of a highly specialized, yet geographically
diffused, discipline, AML/CFT professionals have found it
challenging to accurately gauge their compensation relative
to that of their peers. It has been equally difficult for
employers to determine compensation for their AML/CFT
employees, with a vast range of experience and education
represented in this rapidly growing field.
The survey questions progressively drill down to the
various titles and responsibilities in the AML and
compliance field. An in-depth, comparative analysis of job
title, years of experience, certification, skill set, level
in an organization, and type of business will serve as a
useful barometer for professionals in different geographic
regions and help differentiate between public and private
sector job compensation.
To ensure the integrity of the survey, ACAMS has
contracted The Dihedral Group to administer the survey, and
to collect, assess, and analyze individual responses. Survey
results will be published only in aggregate, with individual
responses being consolidated to ensure complete
confidentiality.
To view and/or take the survey, go to
http://www.acams.org .
ABOUT ACAMS
ACAMS is an international membership organization
dedicated to enhancing the knowledge and skills of AML
professionals around the globe. It serves as a uniquely
valuable resource for thousands of members from more than
100 countries, promoting year-round support to develop and
sharpen the skills required for superior job performance
and career advancement. Its CAMS certification is the most
widely recognized AML certification among compliance
professionals worldwide.
For more information, please contact:
Christine Michaels
ACAMS
Tel: +1-305-373-0020 Ext. 3061
2007'08.24.Fri
(有)糸島みるくぷらんと（福岡県 代表取締役 宮崎英文）は、「バター作り体験キット」を新発売。
「低温殺菌ノンホモ牛乳伊都物語」は、生乳に近い牛乳で、バターができます。
スーパーで大量販売されている牛乳との違いを体験してください。
本文：
１．「バター作り体験キット」新発売
しぼりたてに近い牛乳は、バターを作ることができます。
そこで、伊都物語の低温殺菌ノンホモ牛乳と、わかりやすい説明書、その他必要なキャップやストローなどをセットにして発売いたします。
２．バターができる理由
しぼりたての生乳は、静置しておくと「クリームライン」と呼ばれる生クリームの層が、上部にできます。
これは、乳脂肪が集まってきてできるものです。
乳脂肪は、牛乳の中ではたんぱく質のまくに包まれています。そのまくを壊してやることによって、脂肪分が集まりバターができます。
一般に売られている牛乳は、大量生産するために短時間で高温殺菌します。そのためには、脂肪球を粉々に小さく砕く必要があります。脂肪球を砕いているのでバターはできません。
低温殺菌ノンホモ牛乳は、低温でじっくり殺菌するため、脂肪球を壊す必要がありません。このノンホモ牛乳から、バターを作ることができます。
３．低温殺菌ノンホモ牛乳伊都物語について
「低温殺菌ノンホモ牛乳伊都物語」は、福岡県糸島地方の酪農家が設立した「糸島みるくぷらんと」が販売しております。より搾りたてに近い牛乳をみなさまにお届けしたいという願いよりつくられました。
結果、たんぱく質やカルシウムがより吸収されやすく、生乳に近い風味も保たれています。
糸島の自然の中で、毎朝搾乳した新鮮な生乳を使用し、手間ひまかけて低温殺菌ノンホモ牛乳を造っております。
「安心・安全・美味しさ・健康」にこだわる伊都物語からの提案です。
■ 問い合わせ先
有限会社 糸島みるくぷらんと
代表取締役 宮崎英文
住 所 〒819-0373 福岡県福岡市西区周船寺１－１３－４
E-mail info@itomonogatari.com
ＴＥＬ 092-807-3911 ＦＡＸ 092-807-5551
関連ＵＲＬ 「伊都物語ホームページ」http://www.itomonogatari.com
「バター作りのページ」 http://www.itomonogatari.com/butter.html
「低温殺菌ノンホモ牛乳伊都物語」は、生乳に近い牛乳で、バターができます。
スーパーで大量販売されている牛乳との違いを体験してください。
本文：
１．「バター作り体験キット」新発売
しぼりたてに近い牛乳は、バターを作ることができます。
そこで、伊都物語の低温殺菌ノンホモ牛乳と、わかりやすい説明書、その他必要なキャップやストローなどをセットにして発売いたします。
２．バターができる理由
しぼりたての生乳は、静置しておくと「クリームライン」と呼ばれる生クリームの層が、上部にできます。
これは、乳脂肪が集まってきてできるものです。
乳脂肪は、牛乳の中ではたんぱく質のまくに包まれています。そのまくを壊してやることによって、脂肪分が集まりバターができます。
一般に売られている牛乳は、大量生産するために短時間で高温殺菌します。そのためには、脂肪球を粉々に小さく砕く必要があります。脂肪球を砕いているのでバターはできません。
低温殺菌ノンホモ牛乳は、低温でじっくり殺菌するため、脂肪球を壊す必要がありません。このノンホモ牛乳から、バターを作ることができます。
３．低温殺菌ノンホモ牛乳伊都物語について
「低温殺菌ノンホモ牛乳伊都物語」は、福岡県糸島地方の酪農家が設立した「糸島みるくぷらんと」が販売しております。より搾りたてに近い牛乳をみなさまにお届けしたいという願いよりつくられました。
結果、たんぱく質やカルシウムがより吸収されやすく、生乳に近い風味も保たれています。
糸島の自然の中で、毎朝搾乳した新鮮な生乳を使用し、手間ひまかけて低温殺菌ノンホモ牛乳を造っております。
「安心・安全・美味しさ・健康」にこだわる伊都物語からの提案です。
■ 問い合わせ先
有限会社 糸島みるくぷらんと
代表取締役 宮崎英文
住 所 〒819-0373 福岡県福岡市西区周船寺１－１３－４
E-mail info@itomonogatari.com
ＴＥＬ 092-807-3911 ＦＡＸ 092-807-5551
関連ＵＲＬ 「伊都物語ホームページ」http://www.itomonogatari.com
「バター作りのページ」 http://www.itomonogatari.com/butter.html
2007'08.24.Fri
紙製のCD・DVDディスクケース －Ably Jacket（エイブリージャケット）－
『For You シリーズ』のオンラインショッピングを開始しました。
本文：
Ably Jacket（エイブリージャケット）は、
CD・DVDディスクのホールド部分（プラスチック）以外の全てが紙でできており
またホールド部分の分離も容易なため、環境保全に寄与する優れたディスクケースといえます。
ディスクを保護する部分は多層構造によりしっかりとした強度を保ち
厚みは5㎜と薄いので、スペースをとりません。
プレゼントやご贈答用にそのままご利用いただけます。
※尚、この商品はオリジナル印刷はできません。
【お問合せ先】
高桑美術印刷株式会社 エイブリージャケット販売促進チーム
本社：TEL：076-248-1274（担当：谷口）
東京：TEL：03-3226-6558（担当：吉田）
http://takakuwa.wave.jp/ably/index.html
E-mail：ably@tk.wave.jp
『For You シリーズ』のオンラインショッピングを開始しました。
本文：
Ably Jacket（エイブリージャケット）は、
CD・DVDディスクのホールド部分（プラスチック）以外の全てが紙でできており
またホールド部分の分離も容易なため、環境保全に寄与する優れたディスクケースといえます。
ディスクを保護する部分は多層構造によりしっかりとした強度を保ち
厚みは5㎜と薄いので、スペースをとりません。
プレゼントやご贈答用にそのままご利用いただけます。
※尚、この商品はオリジナル印刷はできません。
【お問合せ先】
高桑美術印刷株式会社 エイブリージャケット販売促進チーム
本社：TEL：076-248-1274（担当：谷口）
東京：TEL：03-3226-6558（担当：吉田）
http://takakuwa.wave.jp/ably/index.html
E-mail：ably@tk.wave.jp
2007'08.24.Fri
|
|
|
2007'08.24.Fri
簡単にインタラクティブな色塗り分け地図グラフができるツール
『ジョイグラフ(日本地図版)』をバージョンアップし、本日より出荷開始
いたします。
指定地域拡大機能、パワーポイント複数貼付け機能などを追加／変更。
本文：
報道関係者各位
プレスリリース 2007年８月２４日
株式会社タイムランド
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
色塗り分け地図グラフ『ジョイグラフ（日本地図版）』をバージョンアップ
指定地域拡大機能、パワーポイント複数貼付け機能などを追加／変更
http://www.timeland.co.jp/
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
株式会社タイムランド(本社：神奈川県秦野市、代表取締役：川口 浩)は、
簡単にインタラクティブな色塗り分け地図グラフができるツール
『ジョイグラフ(日本地図版)』をバージョンアップし、本日より出荷開始
いたします。
『ジョイグラフ(日本地図版)』は、Adobe Flashで開発され、シンプルで、
軽量、ブラウザに依存しないでインタラクティブな色塗り分け地図グラフが
できる製品です。
■主な機能追加／変更内容
(1)指定した都道府県を中心に拡大する機能を追加
例えば、関東地方のみの地図グラフを作成するなどが可能となります。
拡大中心地域、拡大率を設定ファイルで指定することができます。
拡大は、表示時から、または、日本地図全体を最初に表示し、ズーム
するかを設定ファイルで指定できます。
(2)パワーポイントで複数の地図グラフが表示可能になる機能を追加
以前は、固定ファイル名の設定ファイルのみを対象に表示していたため、
異なるデータの地図グラフを表示できなかったが、異なる設定ファイル名を
読み込めるようにしました。
(3)一部の都道府県のみデータを表示するように機能変更
一部の都道府県のみデータを設定し、表示するように機能を変更しました。
これにより、表示が必要ない都道府県をグレー表示にするなどが可能に
なりました。
(4)設定ファイルの文字コードをUTF-8からShift-JISに変更
UTF-8のテキストファイルを編集するソフトが一般的でないことから
ユーザ様からのご要望で、読み込む文字コードを変更しました。
購入前に、無料で試用することができる試用版を用意しています。試用版に
は、機能制限はなく、すべての機能をお試しいただくことができます。但し、
試用版のみ、画面上に製品ロゴ等が表示されます。
試用版の利用申し込みは、下記URLからできます。
http://www.timeland.co.jp/form/joygraphmapevaluation.html
８月末までの期間限定で、販売キャンペーンを実施中です。
実施内容は以下の通りです。
(1)弊社オンラインショップにて製品価格より1,000円割引
(2)先着1５0本限定で、弊社オリジナル光学式マウス対応マウスパッドを
プレゼント
■商品の仕様
商品名 ： ジョイグラフ(日本地図版) Ｖｅｒ．１．１
発売開始日： 2007年８月２４日
価格 ： ダウンロード版 4,200円(消費税込み)
インストールCD付属版(送料込み) 5,775円(消費税込み)
動作環境 ： Adobe Flash Player 8.0 以上
開発・販売： 株式会社タイムランド
URL ： http://www.timeland.co.jp/
■会社概要
名称 ： 株式会社タイムランド
平成１９年８月２０日より現社名に変更
（旧 有限会社タイムランド）
本社住所 ： 〒257-0014 神奈川県秦野市今泉395-1-403
設立 ： 1995年3月1日
資本金 ： 300万円
代表者 ： 代表取締役 川口 浩
URL ： http://www.timeland.co.jp/
事業内容 ： 視線が動くグラフ、で注目度UP!ジョイグラフ開発、販売
Adobe Flash/Flexを利用したアプリケーション開発
Filemaker Proを利用したアプリケーション開発
その他 ソフトウェア開発及びコンサルティング
秦野スタイル 情報発信推進事業
【本件に関するお問い合わせ先】
株式会社タイムランド
担当者 ： ジョイグラフ担当
TEL ： 0463-84-6481
FAX ： 0463-84-6480
E-MAIL ： joygraph@timeland.co.jp
『ジョイグラフ(日本地図版)』をバージョンアップし、本日より出荷開始
いたします。
指定地域拡大機能、パワーポイント複数貼付け機能などを追加／変更。
本文：
報道関係者各位
プレスリリース 2007年８月２４日
株式会社タイムランド
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
色塗り分け地図グラフ『ジョイグラフ（日本地図版）』をバージョンアップ
指定地域拡大機能、パワーポイント複数貼付け機能などを追加／変更
http://www.timeland.co.jp/
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
株式会社タイムランド(本社：神奈川県秦野市、代表取締役：川口 浩)は、
簡単にインタラクティブな色塗り分け地図グラフができるツール
『ジョイグラフ(日本地図版)』をバージョンアップし、本日より出荷開始
いたします。
『ジョイグラフ(日本地図版)』は、Adobe Flashで開発され、シンプルで、
軽量、ブラウザに依存しないでインタラクティブな色塗り分け地図グラフが
できる製品です。
■主な機能追加／変更内容
(1)指定した都道府県を中心に拡大する機能を追加
例えば、関東地方のみの地図グラフを作成するなどが可能となります。
拡大中心地域、拡大率を設定ファイルで指定することができます。
拡大は、表示時から、または、日本地図全体を最初に表示し、ズーム
するかを設定ファイルで指定できます。
(2)パワーポイントで複数の地図グラフが表示可能になる機能を追加
以前は、固定ファイル名の設定ファイルのみを対象に表示していたため、
異なるデータの地図グラフを表示できなかったが、異なる設定ファイル名を
読み込めるようにしました。
(3)一部の都道府県のみデータを表示するように機能変更
一部の都道府県のみデータを設定し、表示するように機能を変更しました。
これにより、表示が必要ない都道府県をグレー表示にするなどが可能に
なりました。
(4)設定ファイルの文字コードをUTF-8からShift-JISに変更
UTF-8のテキストファイルを編集するソフトが一般的でないことから
ユーザ様からのご要望で、読み込む文字コードを変更しました。
購入前に、無料で試用することができる試用版を用意しています。試用版に
は、機能制限はなく、すべての機能をお試しいただくことができます。但し、
試用版のみ、画面上に製品ロゴ等が表示されます。
試用版の利用申し込みは、下記URLからできます。
http://www.timeland.co.jp/form/joygraphmapevaluation.html
８月末までの期間限定で、販売キャンペーンを実施中です。
実施内容は以下の通りです。
(1)弊社オンラインショップにて製品価格より1,000円割引
(2)先着1５0本限定で、弊社オリジナル光学式マウス対応マウスパッドを
プレゼント
■商品の仕様
商品名 ： ジョイグラフ(日本地図版) Ｖｅｒ．１．１
発売開始日： 2007年８月２４日
価格 ： ダウンロード版 4,200円(消費税込み)
インストールCD付属版(送料込み) 5,775円(消費税込み)
動作環境 ： Adobe Flash Player 8.0 以上
開発・販売： 株式会社タイムランド
URL ： http://www.timeland.co.jp/
■会社概要
名称 ： 株式会社タイムランド
平成１９年８月２０日より現社名に変更
（旧 有限会社タイムランド）
本社住所 ： 〒257-0014 神奈川県秦野市今泉395-1-403
設立 ： 1995年3月1日
資本金 ： 300万円
代表者 ： 代表取締役 川口 浩
URL ： http://www.timeland.co.jp/
事業内容 ： 視線が動くグラフ、で注目度UP!ジョイグラフ開発、販売
Adobe Flash/Flexを利用したアプリケーション開発
Filemaker Proを利用したアプリケーション開発
その他 ソフトウェア開発及びコンサルティング
秦野スタイル 情報発信推進事業
【本件に関するお問い合わせ先】
株式会社タイムランド
担当者 ： ジョイグラフ担当
TEL ： 0463-84-6481
FAX ： 0463-84-6480
E-MAIL ： joygraph@timeland.co.jp
2007'08.24.Fri
全国16才以上の女性を対象に、外食におけるバイキングや食べ放題の利用実態について調査しました。また、普段外食時に興味のある飲食店の形態や、バイキングのよいところ、よくないところ、好きなメニュー・あったらよいと思うメニューなども併せて調査しました。
本文：
１．興味のある飲食店のタイプは第1位が「回転寿司」。僅差で「ファミリーレストラン」が続く。
全員に対し、外食の際に興味がある飲食店のタイプを複数回答でたずねたところ以下のような結果となった。
最も多かった回答は「回転寿司」で、66.2%の人が「興味がある」と回答した。第2位は僅差で「ファミリーレストラン」(65.6%)となった。以下、「ラーメン店」(58.7%)、「焼肉店」(55.8%)、「洋食店」(54.6%)、「中華料理店」(54.3%)の順で続く。
２．レストランのドリンクバー利用経験者の利用頻度は「2～3ヶ月に1回程度」が25.3 %。
続いてレストランのドリンクバーを利用したことがあると回答した221名に、その利用頻度をたずねたところ、「2～3ヶ月に1回程度」の回答が最も多く、25.3%となった。次いで「1年に2～3回程度」、「それ以下（1年に1回以下）」(ともに17.2%)、「月1回程度」(15.8%)、「月2～3回程度」(13.6%)の順となった。
３．ホテルのランチバイキング利用経験者の利用頻度は「1年に1回程度」が25.0%。「それ以下」が34.8%
続いてホテルのランチバイキングを利用したことがあると回答した204名に、その利用頻度をたずねたところ、「それ以下（1年に1回以下）」の回答が最も多く、34.8%となった。次いで「1年に1回程度」(25.0%)、「1年に2～3回程度」(22.5%)の順となった。
４．バイキングで好きなもの・あるとよいものは「ケーキ」が第1位。次いで「ドリンクバー（ソフトドリンク）」、「フルーツ」、「サラダ」の順。
続いて全員にバイキングで好きなもの・あるとよいものを聞いたところ、結果は以下の通り。
第1位は「ケーキ」(69.4%)、次いで「ドリンクバー（ソフトドリンク）」(66.9%)、「フルーツ」(62.1%)、「サラダ」(60.9%)、「アイスクリーム」(58.0%)の順となり、デザートやフルーツが多く上位にランクインする結果となった。
◆◆調査概要◆◆
調査方法 ： 小社保有の「ＭＤＢネットサーベイ」利用によるインターネットリサーチ
調査対象エリア： 全国
調査対象者 ： １６才以上の女性
サンプル数 ： ３１７票（有効回答数）
調査実施期間 ： ２００７年８月１０日～８月１３日
本文：
１．興味のある飲食店のタイプは第1位が「回転寿司」。僅差で「ファミリーレストラン」が続く。
全員に対し、外食の際に興味がある飲食店のタイプを複数回答でたずねたところ以下のような結果となった。
最も多かった回答は「回転寿司」で、66.2%の人が「興味がある」と回答した。第2位は僅差で「ファミリーレストラン」(65.6%)となった。以下、「ラーメン店」(58.7%)、「焼肉店」(55.8%)、「洋食店」(54.6%)、「中華料理店」(54.3%)の順で続く。
２．レストランのドリンクバー利用経験者の利用頻度は「2～3ヶ月に1回程度」が25.3 %。
続いてレストランのドリンクバーを利用したことがあると回答した221名に、その利用頻度をたずねたところ、「2～3ヶ月に1回程度」の回答が最も多く、25.3%となった。次いで「1年に2～3回程度」、「それ以下（1年に1回以下）」(ともに17.2%)、「月1回程度」(15.8%)、「月2～3回程度」(13.6%)の順となった。
３．ホテルのランチバイキング利用経験者の利用頻度は「1年に1回程度」が25.0%。「それ以下」が34.8%
続いてホテルのランチバイキングを利用したことがあると回答した204名に、その利用頻度をたずねたところ、「それ以下（1年に1回以下）」の回答が最も多く、34.8%となった。次いで「1年に1回程度」(25.0%)、「1年に2～3回程度」(22.5%)の順となった。
４．バイキングで好きなもの・あるとよいものは「ケーキ」が第1位。次いで「ドリンクバー（ソフトドリンク）」、「フルーツ」、「サラダ」の順。
続いて全員にバイキングで好きなもの・あるとよいものを聞いたところ、結果は以下の通り。
第1位は「ケーキ」(69.4%)、次いで「ドリンクバー（ソフトドリンク）」(66.9%)、「フルーツ」(62.1%)、「サラダ」(60.9%)、「アイスクリーム」(58.0%)の順となり、デザートやフルーツが多く上位にランクインする結果となった。
◆◆調査概要◆◆
調査方法 ： 小社保有の「ＭＤＢネットサーベイ」利用によるインターネットリサーチ
調査対象エリア： 全国
調査対象者 ： １６才以上の女性
サンプル数 ： ３１７票（有効回答数）
調査実施期間 ： ２００７年８月１０日～８月１３日
2007'08.24.Fri
株式会社エコロジカルプレゼンツは、健康・環境関連商品を販売するネットショップ「Peco Shop はならいふ Yahoo支店」「Peco Shop 楽天支店」両店で、シベリア人参エキス使用の健康食品『抗糖露アディアＳ』をお手頃価格でご提供。キャンペーンは8月31日まで。
本文：
健康・環境関連商品の販売を手掛ける株式会社エコロジカルプレゼンツ（本社：神奈川県川崎市多摩区、代表取締役：木村博昭）は、当社が運営するネットショップ「Peco Shop はならいふ Yahoo支店」（http://store.yahoo.co.jp/eco-presents/）および「Peco Shop 楽天支店」（http://www.rakuten.co.jp/peco/）にて、話題の健康食品「シベリア人参エキス『抗糖露アディアＳ』」をお手頃価格で提供する「夏バテ撃退キャンペーン」を８月末まで実施しています。
「シベリア人参エキス『抗糖露アディアＳ』」は、糖尿病対策やメタボリック対策などで学会でも注目を集めている健康食品で、当ショップの「一押し商品」となっています。今回の「夏バテ撃退キャンペーン」では、夏本番を迎え、何かと体調を崩しがちなこの季節に、より多くの方に「シベリア人参エキス『抗糖露アディアＳ』」の優れたパワーで暑い夏を乗り切ってもらえれば、との思いから、同商品をお手頃価格で提供させて頂きます。
販売価格は、全国送料込み・通常価格２個セット25,200円のところ24,600円で、3個セットで37,800円のところ34,200円で、５個セット63,000円のところ54,000円となります。（最大15％引き）。キャンペーン実施期間は2007年8月1日より8月31日まで。
またと無いこの機会に、「シベリア人参エキス『抗糖露アディアＳ』」の優れたパワーを是非お試し下さい。
～リリースに関するお問い合わせ先～
株式会社エコロジカルプレゼンツ 担当：広報室 岡崎
〒214-0014 神奈川県川崎市多摩区登戸2663
電話 044-930-7721
ｅ-mail okazaki@eco-presents.co.jp
ＵＲＬ: http://www.eco-presents.co.jp/
本文：
健康・環境関連商品の販売を手掛ける株式会社エコロジカルプレゼンツ（本社：神奈川県川崎市多摩区、代表取締役：木村博昭）は、当社が運営するネットショップ「Peco Shop はならいふ Yahoo支店」（http://store.yahoo.co.jp/eco-presents/）および「Peco Shop 楽天支店」（http://www.rakuten.co.jp/peco/）にて、話題の健康食品「シベリア人参エキス『抗糖露アディアＳ』」をお手頃価格で提供する「夏バテ撃退キャンペーン」を８月末まで実施しています。
「シベリア人参エキス『抗糖露アディアＳ』」は、糖尿病対策やメタボリック対策などで学会でも注目を集めている健康食品で、当ショップの「一押し商品」となっています。今回の「夏バテ撃退キャンペーン」では、夏本番を迎え、何かと体調を崩しがちなこの季節に、より多くの方に「シベリア人参エキス『抗糖露アディアＳ』」の優れたパワーで暑い夏を乗り切ってもらえれば、との思いから、同商品をお手頃価格で提供させて頂きます。
販売価格は、全国送料込み・通常価格２個セット25,200円のところ24,600円で、3個セットで37,800円のところ34,200円で、５個セット63,000円のところ54,000円となります。（最大15％引き）。キャンペーン実施期間は2007年8月1日より8月31日まで。
またと無いこの機会に、「シベリア人参エキス『抗糖露アディアＳ』」の優れたパワーを是非お試し下さい。
～リリースに関するお問い合わせ先～
株式会社エコロジカルプレゼンツ 担当：広報室 岡崎
〒214-0014 神奈川県川崎市多摩区登戸2663
電話 044-930-7721
ｅ-mail okazaki@eco-presents.co.jp
ＵＲＬ: http://www.eco-presents.co.jp/
2007'08.24.Fri
オーケーズデリカ「食品安全マネージメントシステム」認証
| 2007年08月23日 ――――――――――――――――――――――――――――― ◆ケータリング業界初！ 衛生・安全面に特化した「ISO22000」認証取得 肉の表示や製造に関する偽装問題や、大量の化学物質を含んだ加工食品輸入 オーケーズデリカでは、このような食に対する不安が広がる以前の２００５年 【 オーケーズデリカ HACCP認定工場・製造工程 】 １． 「食材の入荷」「検品開梱」と進み、「冷蔵保存」「加熱処理」の ２． 「急速冷凍」「コールドキッチン」「一時保管」「盛り付け」と ３． 最終的な品質・衛生チェックを行う「出荷準備」工程を経て、 ◆徹底した管理で、細菌の侵入・汚染、異物の混入から食品を守る 食品業界にとってこの時期は、Ｏ-１５７や食中毒の発生には最も気をつけ 「今後も弁当・給食の安全性とおいしさをさらに追及し、顧客満足度を重視 《ご担当記者様へ》 食品加工業界やケータリング業界の食の安全にまつわる |
2007'08.24.Fri
府中のハウスクリーニングとリフォームの株式会社全日美
| 2007年08月23日 府中のハウスクリーニングとリフォーム会社です。府中市周辺（調布市、多摩市、国立市、国分寺市、小金井市、三鷹市、武蔵野市、立川市、日野市、八王子市など）のハウスクリーニングやリフォームを取扱っています。 |
2007'08.24.Fri
府中市の害虫駆除、防カビ、消毒の株式会社全日美
| 2007年08月23日 府中市周辺（調布市、多摩市、国立市、国分寺市、小金井市、三鷹市、武蔵野市、立川市、日野市、八王子市など）の害虫駆除、防カビ、消毒、エアコンクリーニングやルームクリーニング、庭木等を取扱っています。 |
広告
ブログ内検索
アーカイブ
カウンター